文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

日本儿童肝脏肿瘤研究组2方案治疗肝母细胞瘤的结局与晚期并发症

Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol.
PubMed 文献 · J Clin Oncol · 2020-05-18

该研究纳入1999至2012年361例初治肝母细胞瘤患者,按PRETEXT分层采用顺铂-四氢吡喃阿霉素(CITA)为基础的方案。5年无事件生存率和总生存率在分层1为74.2%和89.9%,分层2为84.8%和90.8%,分层3为71.6%和85.9%,分层4为59.1%和67.3%。CITA应答者结局显著优于无应答者,晚期耳毒性、心脏毒性和生长迟缓分别发生于61、18和47例患者,发生13例第二恶性肿瘤(含10例白血病)。

要点

  • PRETEXT I/II无标注因素患者可实现 upfront 切除,CITA应答者生存满意。
  • CITA无应答者即使接受ITEC方案和干细胞移植挽救,结局仍不理想。
  • JPLT-2方案心脏毒性发生率相对较低,但第二恶性肿瘤发生率较高。

核心结论

  • JPLT-2方案在无标注因素的PRETEXT I/II患者中实现了 upfront 可切除性,在其余患者中对CITA应答者取得了满意生存。
  • CITA无应答者即使接受ITEC方案和干细胞移植强化治疗,结局仍不满意。
  • JPLT-2方案心脏毒性发生率相对较低,但第二恶性肿瘤发生率较高。

研究设计与样本

  • 日本儿童肝脏肿瘤研究组(JPLT)-2方案的多中心研究,1999年至2012年纳入361例初治肝母细胞瘤患者。
  • 根据PRETEXT分类进行风险分层,采用顺铂-四氢吡喃阿霉素(CITA)为基础的化疗。

主要发现

  • 5年无事件生存率和总生存率:分层1为74.2%和89.9%,分层2为84.8%和90.8%,分层3为71.6%和85.9%,分层4为59.1%和67.3%。
  • CITA应答者结局显著优于无应答者。
  • 晚期耳毒性、心脏毒性和生长迟缓分别发生于61例、18例和47例患者。
  • 发生13例第二恶性肿瘤,包括10例白血病,与更高的吡柔比星暴露和诊断时年龄较小相关。

关键数值与推荐

  • PRETEXT I/II患者接受 upfront 切除后低剂量CITA(分层1)或接受低剂量CITA后手术及术后化疗(分层2)。
  • 其余患者接受2周期CITA后,应答者接受CITA方案再切除(分层3),无应答者换用异环磷酰胺、吡柔比星、依托泊苷和卡铂(ITEC;分层4)。
  • 难治/转移性疾病患者切除后可行自体造血干细胞移植(SCT)强化化疗作为可选治疗。

临床怎么用

  • PRETEXT I/II无标注因素患者可考虑 upfront 切除。
  • CITA应答者可继续CITA方案,无应答者换用ITEC方案。
  • 难治/转移性疾病患者切除后可行自体造血干细胞移植作为可选治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report here the outcomes and late effects of the Japanese Study Group for Pediatric Liver Tumors (JPLT)-2 protocol, on the basis of cisplatin-tetrahydropyranyl-adriamycin (CITA) with risk stratification according to the pretreatment extent of disease (PRETEXT) classification for hepatoblastoma (HB). PATIENTS AND METHODS: From 1999 to 2012, 361 patients with untreated HB were enrolled. PRETEXT I/II patients were treated with up-front resection, followed by low-dose CITA (stratum 1) or received low-dose CITA, followed by surgery and postoperative chemotherapy (stratum 2). In the remaining patients, after 2 cycles of CITA, responders received the CITA regimen before resection (stratum 3), and nonresponders were switched to ifosfamide, pirarubicin, etoposide, and carboplatin (ITEC; stratum 4). Intensified chemotherapeutic regimens with autologous hematopoietic stem-cell transplantation (SCT) after resection were an optional treatment for patients with refractory/metastatic disease. RESULTS: The 5-year event-free and overall survival rates of HB patients were 74.2% and 89.9%, respectively, for stratum 1, 84.8% and 90.8%%, respectively, for stratum 2, 71.6% and 85.9%%, respectively, for stratum 3, and 59.1% and 67.3%%, respectively, for stratum 4. The outcomes for CITA responders were significantly better than those for nonresponders, whose outcomes remained poor despite salvage therapy with a second-line ITEC regimen or SCT. The late effects, ototoxicity, cardiotoxicity, and delayed growth, occurred in 61, 18, and 47 patients, respectively. Thirteen secondary malignant neoplasms (SMNs), including 10 leukemia, occurred, correlating with higher exposure to pirarubicin and younger age at diagnosis. CONCLUSION: The JPLT-2 protocol achieved up-front resectability in PRETEXT I/II patients with no annotation factors, and satisfactory survival in patients who were CITA responders in the remaining patients. However, outcomes for CITA nonresponders were unsatisfactory, despite therapy intensification with ITEC regimens and SCT. JPLT-2 had a relatively low incidence of cardiotoxicity but high rates of SMNs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hiyama E, Hishiki T, Watanabe K, et al. Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol. J Clin Oncol. 2020. PMID: 32421442. doi:10.1200/JCO.19.01067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。